Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
272 questions in 49 reviews · Heart
current versionsNo studies 272 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Beta‐blockers vs placebo or no intervention Serious adverse events at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction Beta‐blockers for suspected or diagnosed acute myocardial infarction (2019) · Cochrane | no estimate extracted | NR | No studies |
Beta‐blockers vs placebo or no intervention MACE (major adverse cardiovascular event) at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction Beta‐blockers for suspected or diagnosed acute myocardial infarction (2019) · Cochrane | no estimate extracted | NR | No studies |
Beta‐blockers vs placebo or no intervention Quality of life at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction Beta‐blockers for suspected or diagnosed acute myocardial infarction (2019) · Cochrane | no estimate extracted | NR | No studies |
Beta‐blockers vs placebo or no intervention Serious adverse events at maximum · patients with suspected or diagnosed myocardial infarction Beta‐blockers for suspected or diagnosed acute myocardial infarction (2019) · Cochrane | no estimate extracted | NR | No studies |
Transcatheter aortic valve implantation vs surgical aortic valve replacement Outcomes (up to 30 days' · adults with severe aortic stenosis who are at a low surgical risk. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis… (2019) · Cochrane | no estimate extracted | NR | No studies |
Exercise‐based cardiac rehabilitation vs usual care Mortality due to all causes ‐ not reported · people with implantable ventricular assist devices Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices (2018) · Cochrane | no estimate extracted | NR | No studies |
Exercise‐based cardiac rehabilitation vs usual care Mortality due to cardiovascular event ‐ not reported · people with implantable ventricular assist devices Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices (2018) · Cochrane | no estimate extracted | NR | No studies |
Exercise‐based cardiac rehabilitation vs usual care Rehospitalisation due to cardiovascular event ‐ not reported · people with implantable ventricular assist devices Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices (2018) · Cochrane | no estimate extracted | NR | No studies |
Exercise‐based cardiac rehabilitation vs usual care Serious adverse events: infection · people with implantable ventricular assist devices Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices (2018) · Cochrane | no estimate extracted | NR | No studies |
Exercise‐based cardiac rehabilitation vs usual care Heart transplantation ‐ not reported · people with implantable ventricular assist devices Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices (2018) · Cochrane | no estimate extracted | NR | No studies |
Exercise‐based cardiac rehabilitation vs usual care Cost ‐ not reported · people with implantable ventricular assist devices Exercise‐based cardiac rehabilitation for people with implantable ventricular assist devices (2018) · Cochrane | no estimate extracted | NR | No studies |
ICD plus optimal medical therapy vs optimal medical therapy alone Outcomes length of · people with non‐ischaemic cardiomyopathy Implantable cardiac defibrillators for people with non‐ischaemic cardiomyopathy (2018) · Cochrane | no estimate extracted | NR | No studies |
ICD plus optimal medical therapy vs optimal medical therapy alone First ICD‐related hospitalisation ‐ not reported · people with non‐ischaemic cardiomyopathy Implantable cardiac defibrillators for people with non‐ischaemic cardiomyopathy (2018) · Cochrane | no estimate extracted | NR | No studies |
Exercise‐based cardiac rehabilitation vs usual care Return to work · adults with stable angina Exercise‐based cardiac rehabilitation for adults with stable angina (2018) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Total and cardiovascular mortality · Overweight or obese adults Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Unstable angina · Adults with coronary heart disease Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Coronary artery bypass graft surgery · Adults with coronary heart disease Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Percutaneous transluminal coronary angioplasty · Adults with coronary heart disease Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Stroke · Adults with coronary heart disease Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Adverse events · Adults with coronary heart disease Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Fatal and nonfatal myocardial infarction · Overweight or obese adults Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Unstable angina · Overweight or obese adults Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Coronary artery bypass graft surgery · Overweight or obese adults Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Percutaneous transluminal coronary angioplasty · Overweight or obese adults Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Stroke · Overweight or obese adults Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Total and cardiovascular mortality · Adults with coronary heart disease Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Low GI vs high GI Fatal and nonfatal myocardial infarction · Adults with coronary heart disease Low glycaemic index diets for the prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Total cardiovascular mortality · Free‐living adults who were healthy, had established cardiovascular disease or risk factors for cardiovascular disease Whole grain cereals for the primary or secondary prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Fatal and non‐fatal myocardial infarction · Free‐living adults who were healthy, had established cardiovascular disease or risk factors for cardiovascular disease Whole grain cereals for the primary or secondary prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Unstable angina · Free‐living adults who were healthy, had established cardiovascular disease or risk factors for cardiovascular disease Whole grain cereals for the primary or secondary prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Coronary artery bypass graft surgery · Free‐living adults who were healthy, had established cardiovascular disease or risk factors for cardiovascular disease Whole grain cereals for the primary or secondary prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Percutaneous transluminal coronary angioplasty · Free‐living adults who were healthy, had established cardiovascular disease or risk factors for cardiovascular disease Whole grain cereals for the primary or secondary prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Stroke · Free‐living adults who were healthy, had established cardiovascular disease or risk factors for cardiovascular disease Whole grain cereals for the primary or secondary prevention of cardiovascular disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Adenosine vs calcium channel antagonists Length of stay in hospital · patients with supraventricular tachycardia Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia (2017) · Cochrane | no estimate extracted | NR | No studies |
Adenosine vs calcium channel antagonists Patient satisfaction · patients with supraventricular tachycardia Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia (2017) · Cochrane | no estimate extracted | NR | No studies |
Enalapril plus folic acid vs enalapril First unstable angina pectoris episode requiring hospitalisation · adults with hypertension Homocysteine‐lowering interventions for preventing cardiovascular events (2017) · Cochrane | no estimate extracted | NR | No studies |
Homocysteine‐lowering interventions (high dose) vs homocysteine‐lowering interventions (low dose) Cancer · adults at risk of or with established cardiovascular disease Homocysteine‐lowering interventions for preventing cardiovascular events (2017) · Cochrane | no estimate extracted | NR | No studies |
Beta‐blockers vs placebo, no treatment or surveillance only Outcomes · people with confirmed diagnosis of Marfan syndrome Beta‐blockers for preventing aortic dissection in Marfan syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Ranolazine (add‐on therapy) vs placebo Cardiovascular mortality ‐ not reported · patients with stable angina pectoris Ranolazine for stable angina pectoris (2017) · Cochrane | no estimate extracted | NR | No studies |
Ranolazine (add‐on therapy) vs placebo Non‐cardiovascular mortality ‐ not reported · patients with stable angina pectoris Ranolazine for stable angina pectoris (2017) · Cochrane | no estimate extracted | NR | No studies |
Ranolazine (monotherapy) vs placebo Non‐cardiovascular mortality ‐ not reported · patients with stable angina pectoris Ranolazine for stable angina pectoris (2017) · Cochrane | no estimate extracted | NR | No studies |
Drug‐eluting stents vs bare‐metal stents Quality of life at maximum · People with acute coronary syndrome Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Drug‐eluting stents vs bare‐metal stents Angina at maximum · People with acute coronary syndrome Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome (2017) · Cochrane | no estimate extracted | NR | No studies |
Sexual counselling vs usual care Satisfaction in how sexual issues are addressed in cardiac rehabilitation services (Satisfaction with health services) · participants with cardiovascular disease Sexual counselling for sexual problems in patients with cardiovascular disease (2016) · Cochrane | no estimate extracted | NR | No studies |
Lidocaine vs disopyramide Overall survival at 30 days after myocardial infarction · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane | no estimate extracted | NR | No studies |
Lidocaine vs tocainide Overall survival at 30 days after myocardial infarction · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane | no estimate extracted | NR | No studies |
Lidocaine vs tocainide Ventricular fibrillation · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane | no estimate extracted | NR | No studies |
Lidocaine vs mexiletine Overall survival at 30 days after myocardial infarction · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane | no estimate extracted | NR | No studies |
Lidocaine vs propafenone All‐cause mortality · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane | no estimate extracted | NR | No studies |
Lidocaine vs propafenone Cardiac mortality · patients with myocardial infarction Prophylactic lidocaine for myocardial infarction (2015) · Cochrane | no estimate extracted | NR | No studies |